These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15128019)

  • 1. Detection of specific IgE antibodies to nafamostat mesilate as an indication of possible adverse effects of leukocytapheresis using nafamostat mesilate as anticoagulant.
    Nagase K; Fukunaga K; Ohnishi K; Kusaka T; Matoba Y; Sawada K
    Ther Apher Dial; 2004 Feb; 8(1):45-51. PubMed ID: 15128019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study.
    Sawada K; Ohdo M; Ino T; Nakamura T; Numata T; Shibata H; Sakou J; Kusada M; Hibi T
    Ther Apher Dial; 2016 Apr; 20(2):197-204. PubMed ID: 26771066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.
    Ashizuka S; Nishiura R; Ishikawa N; Yamaga J; Inatsu H; Fujimoto S; Eto T
    Ther Apher Dial; 2006 Feb; 10(1):54-8. PubMed ID: 16556137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis.
    Kanke K; Hoshino M; Tominaga K; Nakano M; Terano A; Hiraishi H
    Blood Purif; 2007; 25(4):370-6. PubMed ID: 17785966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe abdominal pain associated with allergic reaction to nafamostat mesilate in a chronic hemodialysis patient.
    Yamazato M; Mano R; Oshiro-Chinen S; Tomiyama N; Sakima A; Ishida A; Tana T; Tozawa M; Muratani H; Iseki K; Takishita S
    Intern Med; 2002 Oct; 41(10):864-6. PubMed ID: 12413011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked eosinophilia induced by nafamostat mesilate, an anticoagulant in a hemodialysis patient.
    Nakanishi K; Kaneko T; Yano F; Horio M; Kawagoe H; Fujii M; Kashiwai K
    Nephron; 1992; 62(1):97-9. PubMed ID: 1436301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complications of leukocytapheresis.
    Nagase K; Sawada K; Ohnishi K; Egashira A; Ohkusu K; Shimoyama T
    Ther Apher; 1998 May; 2(2):120-4. PubMed ID: 10225712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of leukocytapheresis in suppressing the occurrence of surgical site infections following surgery for ulcerative colitis.
    Itabashi M; Ikeuchi H; Araki T; Kono T; Nakamura T; Takesue Y; Kameoka S; Kusunoki M
    Surg Today; 2008; 38(7):609-17. PubMed ID: 18612785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.
    Lee YK; Lee HW; Choi KH; Kim BS
    PLoS One; 2014; 9(10):e108737. PubMed ID: 25302581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
    Maruyama Y; Yoshida H; Uchino S; Yokoyama K; Yamamoto H; Takinami M; Hosoya T
    Int J Artif Organs; 2011 Jul; 34(7):571-6. PubMed ID: 21786254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
    Hwang SD; Hyun YK; Moon SJ; Lee SC; Yoon SY
    Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New technique of leukocytapheresis by the use of nonwoven polyester fiber filter for inflammatory bowel disease.
    Kawamura A; Saitoh M; Yonekawa M; Horie T; Ohizumi H; Tamaki T; Kukita K; Meguro J
    Ther Apher; 1999 Nov; 3(4):334-7. PubMed ID: 10608731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis.
    Kobayashi T; Matsuoka K; Yokoyama Y; Nakamura T; Ino T; Numata T; Shibata H; Aoki H; Matsuno Y; Hibi T
    J Gastroenterol; 2018 Mar; 53(3):387-396. PubMed ID: 28597225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy.
    Makino S; Egi M; Kita H; Miyatake Y; Kubota K; Mizobuchi S
    Int J Artif Organs; 2016 Jan; 39(1):16-21. PubMed ID: 26868216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of inflammatory bowel disease by leukocytapheresis.
    Gerçeker E; Yüceyar H; Kasap E; Demirci U; Ekti BC; Aydoğdu İ; Miskioğlu M
    Transfus Apher Sci; 2017 Jun; 56(3):421-426. PubMed ID: 28454883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial.
    Choi JY; Kang YJ; Jang HM; Jung HY; Cho JH; Park SH; Kim YL; Kim CD
    Medicine (Baltimore); 2015 Dec; 94(52):e2392. PubMed ID: 26717390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass.
    Kikura M; Tanaka K; Hiraiwa T; Tanaka K
    J Cardiothorac Vasc Anesth; 2012 Apr; 26(2):239-44. PubMed ID: 22019206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Univariate analysis to examine predictors of response to leukocytapheresis in ulcerative colitis patients.
    Nagayama K; Takedatsu H; Mitsuyama K; Yamasaki H; Kuwaki K; Yoshioka S; Kobayashi T; Yamauchi R; Kakuma T; Sata M
    Ther Apher Dial; 2014 Jun; 18(3):244-51. PubMed ID: 24965290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adsorption of Nafamostat Mesilate on AN69ST Membranes: A Single-Center Retrospective and In Vitro Study.
    Nakamura Y; Hara S; Hatomoto H; Yamasaki S; Nakano T; Miyazaki M; Matsumoto N; Irie Y; Ishikura H
    Ther Apher Dial; 2017 Dec; 21(6):620-627. PubMed ID: 28960755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nafamostat mesilate, a potent serine protease inhibitor, inhibits airway eosinophilic inflammation and airway epithelial remodeling in a murine model of allergic asthma.
    Ishizaki M; Tanaka H; Kajiwara D; Toyohara T; Wakahara K; Inagaki N; Nagai H
    J Pharmacol Sci; 2008 Nov; 108(3):355-63. PubMed ID: 19008643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.